Following the diagnosis of intracranial hypertension acetazolamide 1 g per day was begun. An increase in dosage to 500 mg four times a day was not tolerated. After 6 weeks of acetazolamide treatment the patient noted onset of a shadow near fixation in the right eye. Visual acuity at this time was 20/20 in each eye with a relative afferent defect of 1 2 log units in the right eye. Fundus examination revealed papilloedema greater in the right eye than the left, with dilated disc vessels and a small vitreous haemorrhage overlying the right disc and inferior retina. A computed tomogram of the brain revealed no intracranial haemorrhage or other abnormality.
Case report A 19-year-old, non-obese white man was followed for 2 years for idiopathic CIDP characterised by recurrent proximal and distal weakness, distal numbness, areflexia, and decreased pin prick and vibration sensation of the feet. Electrodiagnostic studies supporting the diagnosis of CIDP included marked non Following the diagnosis of intracranial hypertension acetazolamide 1 g per day was begun. An increase in dosage to 500 mg four times a day was not tolerated. After 6 weeks of acetazolamide treatment the patient noted onset of a shadow near fixation in the right eye. Visual acuity at this time was 20/20 in each eye with a relative afferent defect of 1 2 log units in the right eye. Fundus examination revealed papilloedema greater in the right eye than the left, with dilated disc vessels and a small vitreous haemorrhage overlying the right disc and inferior retina. A computed tomogram of the brain revealed no intracranial haemorrhage or other abnormality.
Owing to increasing relative afferent pupillary defect during maximum tolerated medical therapy, a right optic nerve sheath decompression was performed through a lateral orbitotomy approach. Papilloedema decreased and visual fields improved in both eyes with a reduction of the afferent pupillary defect to 0-6 log units. The patient did not require acetazolamide postoperatively.
Comment
Papilloedema and intracranial hypertension are uncommon but well recognised complications of the acute inflammatory demyelinating polyneuropathy entity, the Guillain-Barre syndrome. Morley and Reynolds, in a review of 27 GuillainBarre cases, suggested an increased incidence of a relapsing polyneuritis course in these patients. 3 It is unclear whether the concurrent findings of intracranial hypertension and CIDP in our patient represent a chance or a meaningful association. The elevated CSF protein concentration characteristic of Guillain-Barre syndrome has been felt to increase CSF outflow resistance, but Ropper and Marmarou, could attribute no more than 25% of the intracranial pressure rise to measured outflow resistance. They proposed increased venous pressure at points of CSF outflow as an alternative cause of intracranial hypertension in Guillain-Barre syndrome. 4 Regardless of the aetiology of intracranial hypertension, optic nerve sheath fenestration in our patient, as in patients with idiopathic intracranial hypertension, resulted in improvement of papilloedema and prevention of further optic nerve damage.
